Authors


Mehmet Akce, MD

Latest:

Addressing How to Treat Patients With Advanced Hepatocellular Carcinoma

Mehmet Akce, MD, discusses how he treats patients with advanced hepatocellular carcinoma in the first-line setting.


Neeta Somaiah, MD

Latest:

Expanding the Use of Targeted Therapies in GIST

Neeta Somaiah, MD, discusses the expanding role of targeted therapies in patients with gastrointestinal stromal tumor and how these treatments are bolstering later lines of therapy.


Matthew L. Anderson MD, PhD

Latest:

Niraparib Results Encourage Somatic Tumor Profiling in Ovarian Cancer

Matthew Anderson, MD, PhD, discusses how the results with niraparib for patients with advanced ovarian cancer impacts the use of somatic profiling in this patient population.


Badrinath Konety, MD

Latest:

A Deep Dive Into the Evolving Landscape of Prostate Cancer

In season 5, episode 1 of Targeted Talks, Badrinath Konety, MD, delves into the critical topic of prostate cancer screening and discusses some of the recent advancements in the prostate cancer space.


Yuliya Mikheeva, MD

Latest:

Challenges Remain in Treating Anaplastic Thyroid Cancer

Yuliya Mikheeva, MD, PhD, discusses the many challenges oncologists face in treating patients with anaplastic thyroid cancer harboring BRAF mutations.


Christian Buske, MD

Latest:

Ibrutinib Plus Rituximab Data Surprising in Waldenstrom’s Macroglobulinemia

Christian Buske, MD, discusses surprising findings from the 5-Year follow-up of a randomized phase 3 trial in patients with Waldenström’s macroglobulinemia receiving of ibrutinib plus rituximab or placebo plus rituximab.


Karen Kelly, MD

Latest:

Questioning When to Start Immunotherapy for Patients With Oncogenic Drivers

Karen Kelly, MD, discusses how oncogenic drivers affect the use and placement of immunotherapy for patients with lung cancer.


Mark J. Roschewski, MD

Latest:

Copanlisib and Rituximab Show Efficacy in Follicular Lymphoma

Mark J. Roschewski, MD, discusses the preliminary results of a phase 2 trial of copanlisib and rituximab as treatment of patients with untreated follicular lymphoma.


Brea C. Lipe, MD

Latest:

Closing Perspectives on MM Treatment and Care

Brea C. Lipe, MD closes this series highlighting the vast landscape of effective treatments and those on the horizon.



Adam S. DuVall, MD

Latest:

Acute Lymphoblastic Leukemia in Older Adults: Is Chemotherapy-Free Treatment in the Future?

Investigation of intensive chemotherapy regimens has unfortunately resulted in a lack of improvement in outcomes for patients with acute lymphoblastic leukemia in the second of the bimodal peaks.


Alan Bryce, MD

Latest:

PARP Inhibition in Metastatic CRPC: The PROfound and TRITON2 Studies

Expert perspectives on the PROfound and TRITON2 studies of olaparib and rucaparib, respectively, in metastatic castration-resistant prostate cancer.


Adrian Cristian, MD

Latest:

Cristian on the 2023 Miami Cancer Institute Oncology Rehabilitation Symposium

Adrian Cristian, MD, discusses the background of the third annual Miami Cancer Institute Oncology Rehabilitation Symposium and provides an overview of some of the topics that were presented this year.


Minas P. Economides, MD

Latest:

Beyond the First-Line: Economides on Advancing Therapies in RCC

In our 4th episode of Emerging Experts, Minas P. Economides, MD, unveils the challenges and opportunities for renal cell carcinoma treatment, focusing on the lack of therapies available in the second-line setting.


Hong Tang, MD, FACP

Latest:

Skin Toxicity in Cancer Treatment: A Critical Part of Cancer Supportive Care

In contrast to the innovations in cancer treatments that help drive improved survival, there are far fewer innovations targeting toxicities and providing supportive care.


Efrat Luttwak, MD, MPH

Latest:

Bispecific Antibodies Look Promising in Follicular Lymphoma

The use of bispecific antibodies has the potential to revolutionize the management of FL.


Masahiro Tsuboi, MD

Latest:

Phase 3 ADAURA Study Highlights Role for Precision Medicine in EGFR-Positive NSCLC

Masahiro Tsuboi, MD, discusses the findings from the phase 3 ADAURA clinical trial of osimertinib as treatment of patients with EGFR-mutated non–small cell lung cancer.


Andrew Wei, MBBS, PhD

Latest:

MRD Linked to Long-Term Survival With Azacitidine Therapy in AML

Andrew Wei, MBBS, PhD, discusses outcomes related to long-term survival in the QUAZAR AML-001 trial of oral azacitidine in patients with acute myeloid leukemia.


Jeffrey S. Miller, MD

Latest:

Future Directions for NK Cell Platforms in Hematologic Malignancies

Jeffrey Miller, MD, discusses what is next to come following an analysis of GTB-3550.


Bruce Feinberg

Latest:

Manipulating T Cells to Treat Patients With Cancer

Bruce Feinberg, DO, explains how chimeric antigen receptor T cells were introduced in hematologic malignancies.


Pedram Razavi, MD, PhD

Latest:

HR+/HER2- Metastatic Breast Cancer: Future Directions in Care

Closing out their program on HR+/HER2- metastatic breast cancer, panelists look toward future evolutions in the treatment landscape.


Paolo Strati, MD

Latest:

Exploring Novel Combinations in Indolent Lymphomas

Although chemotherapy has represented the standard therapeutic modality for indolent non-Hodgkin lymphoma, monoclonal antibodies, immunomodulatory agents, targeted agents, bispecific antibodies, and cellular therapies are now available.


Nelson J. Chao, MD

Latest:

Navigating Unmet Needs in SR/D cGvHD

Dr Chao provides his insights into the ongoing complexities that clinicians face and shaping a comprehensive understanding of the areas requiring further attention and innovation in cGvHD management.


Evanthia Roussos Torres, MD, PhD

Latest:

What’s Next for the HER2-Negative Breast Cancer Space?

Evanthia Roussos Torres, MD, PhD, discusses the next steps and novel therapies currently showing promise in the HER-2 negative breast cancer space.


Adam Cohen, MD

Latest:

Available CAR T-Cell Therapies in Multiple Myeloma

Adam D. Cohen, MD, discusses the different chimeric antigen receptor T-cell therapies used for multiple myeloma treatment and delves into their potential benefits and risks.


Liza C. Villaruz, MD

Latest:

Areas of Growth in the Management of EGFR-Mutated Lung Cancer

Liza C. Villaruz, MD, discusses what research in the EGFR-positive lung cancer space has recently caught the attention of experts.


John M. Burke, MD

Latest:

And the Award for Most Inspiring Lecture at ASH Goes to…

Ongoing and future trials will attempt to demonstrate the benefi t of NK cell therapies in lymphomas, multiple myeloma, sarcomas, and glioblastoma multiforme, among others.


Lindsey S. Treviño, PhD

Latest:

Disparities in Access to CAR T-Cell Therapy for Patients With Cancer

Lindsey S. Treviño, PhD, discusses some of the disparities that currently exist among patients with cancer.


Firas B. Badin, MD

Latest:

Repotrectinib Shows Improvement Over First-Generation TKIs in ROS1+ NSCLC

Firas B. Badin, MD, discusses the improvements seen with repotrectinib compared with first-generation ROS1-targeting tyrosine kinase inhibitors for patients with advanced ROS1-positive non–small cell lung cancer.


Mehrdad Abedi, MD

Latest:

Exploring the Use of Orca-T for Patients With Acute and Chronic GVHD

Mehrdad Abedi, MD, discusses Orca-T, a high precision cell therapy, for patients with acute and chronic graft-vs-host disease.